These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 27487136)

  • 1. Caveolin-1 promotes Ewing sarcoma metastasis regulating MMP-9 expression through MAPK/ERK pathway.
    Lagares-Tena L; García-Monclús S; López-Alemany R; Almacellas-Rabaiget O; Huertas-Martínez J; Sáinz-Jaspeado M; Mateo-Lozano S; Rodríguez-Galindo C; Rello-Varona S; Herrero-Martín D; Tirado OM
    Oncotarget; 2016 Aug; 7(35):56889-56903. PubMed ID: 27487136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells.
    Tirado OM; Mateo-Lozano S; Villar J; Dettin LE; Llort A; Gallego S; Ban J; Kovar H; Notario V
    Cancer Res; 2006 Oct; 66(20):9937-47. PubMed ID: 17047056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High neuropeptide Y release associates with Ewing sarcoma bone dissemination - in vivo model of site-specific metastases.
    Hong SH; Tilan JU; Galli S; Izycka-Swieszewska E; Polk T; Horton M; Mahajan A; Christian D; Jenkins S; Acree R; Connors K; Ledo P; Lu C; Lee YC; Rodriguez O; Toretsky JA; Albanese C; Kitlinska J
    Oncotarget; 2015 Mar; 6(9):7151-65. PubMed ID: 25714031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.
    Cidre-Aranaz F; Grünewald TG; Surdez D; García-García L; Carlos Lázaro J; Kirchner T; González-González L; Sastre A; García-Miguel P; López-Pérez SE; Monzón S; Delattre O; Alonso J
    Oncogene; 2017 Feb; 36(6):766-776. PubMed ID: 27375017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association between let-7, RAS and HIF-1α in Ewing Sarcoma tumor growth.
    Hameiri-Grossman M; Porat-Klein A; Yaniv I; Ash S; Cohen IJ; Kodman Y; Haklai R; Elad-Sfadia G; Kloog Y; Chepurko E; Feinmesser M; Issakov J; Sher O; Luria D; Kollender Y; Weizman A; Avigad S
    Oncotarget; 2015 Oct; 6(32):33834-48. PubMed ID: 26393682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EWS-FLI1-mediated tenascin-C expression promotes tumour progression by targeting MALAT1 through integrin α5β1-mediated YAP activation in Ewing sarcoma.
    He S; Huang Q; Hu J; Li L; Xiao Y; Yu H; Han Z; Wang T; Zhou W; Wei H; Xiao J
    Br J Cancer; 2019 Nov; 121(11):922-933. PubMed ID: 31649319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EWS-FLI1 positively regulates autophagy by increasing ATG4B expression in Ewing sarcoma cells.
    Lu Q; Zhang Y; Ma L; Li D; Li M; Li J; Liu P
    Int J Mol Med; 2017 Oct; 40(4):1217-1225. PubMed ID: 28902354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caveolin-1 modulates the ability of Ewing's sarcoma to metastasize.
    Sáinz-Jaspeado M; Lagares-Tena L; Lasheras J; Navid F; Rodriguez-Galindo C; Mateo-Lozano S; Notario V; Sanjuan X; Garcia Del Muro X; Fabra A; Tirado OM
    Mol Cancer Res; 2010 Nov; 8(11):1489-500. PubMed ID: 21106507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysyl oxidase is downregulated by the EWS/FLI1 oncoprotein and its propeptide domain displays tumor supressor activities in Ewing sarcoma cells.
    Agra N; Cidre F; García-García L; de la Parra J; Alonso J
    PLoS One; 2013; 8(6):e66281. PubMed ID: 23750284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-193b, downregulated in Ewing Sarcoma, targets the ErbB4 oncogene to inhibit anchorage-independent growth.
    Moore C; Parrish JK; Jedlicka P
    PLoS One; 2017; 12(5):e0178028. PubMed ID: 28542597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
    Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK
    Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model.
    Takigami I; Ohno T; Kitade Y; Hara A; Nagano A; Kawai G; Saitou M; Matsuhashi A; Yamada K; Shimizu K
    Int J Cancer; 2011 Jan; 128(1):216-26. PubMed ID: 20648560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EphA2-induced angiogenesis in ewing sarcoma cells works through bFGF production and is dependent on caveolin-1.
    Sáinz-Jaspeado M; Huertas-Martinez J; Lagares-Tena L; Martin Liberal J; Mateo-Lozano S; de Alava E; de Torres C; Mora J; Del Muro XG; Tirado OM
    PLoS One; 2013; 8(8):e71449. PubMed ID: 23951165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caveolin-1 regulating the invasion and expression of matrix metalloproteinase (MMPs) in pancreatic carcinoma cells.
    Han F; Zhu HG
    J Surg Res; 2010 Mar; 159(1):443-50. PubMed ID: 20031158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1.
    Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B
    Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
    Kovar H
    Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targeting.
    Theisen ER; Pishas KI; Saund RS; Lessnick SL
    Oncotarget; 2016 Apr; 7(14):17616-30. PubMed ID: 26848860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma.
    Garcia-Monclús S; López-Alemany R; Almacellas-Rabaiget O; Herrero-Martín D; Huertas-Martinez J; Lagares-Tena L; Alba-Pavón P; Hontecillas-Prieto L; Mora J; de Álava E; Rello-Varona S; Giangrande PH; Tirado OM
    Int J Cancer; 2018 Sep; 143(5):1188-1201. PubMed ID: 29582409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of Wnt/β-Catenin in Ewing Sarcoma Cells Antagonizes EWS/ETS Function and Promotes Phenotypic Transition to More Metastatic Cell States.
    Pedersen EA; Menon R; Bailey KM; Thomas DG; Van Noord RA; Tran J; Wang H; Qu PP; Hoering A; Fearon ER; Chugh R; Lawlor ER
    Cancer Res; 2016 Sep; 76(17):5040-53. PubMed ID: 27364557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.